MENSHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 29 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Jyong Biotech Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (70): Smaller than most of the companies we track.
Volatility (8): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MENS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MENS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Jyong Biotech Ltd. returned −96.2% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 80% of US stocks
Higher than 25% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Jyong Biotech Ltd. has a market value of $145.2M and an enterprise value of $159.2M.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Jyong Biotech Ltd. employs 27 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Jyong Biotech Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Jyong Biotech announced two investor events: Oct. 24, 2026, in Mountain View, California, and Oct. 25, 2026, in Irvine, California.
Why it matters — MENS watchers may note the company’s planned investor events in California.
Jyong Biotech announced plans to establish a potential manufacturing facility and U.S. operations center in Texas. The initiative is intended to support U.S. operations and potential future commercialization of its investigational drug candidates, if approved.
Why it matters — MENS watchers may note the proposed Texas facility as part of the company’s preparations for potential U.S. commercialization.
Jyong Biotech Ltd. announced its participation in a StockFan Virtual Investor Non-Deal Roadshow, with the company based in New Taipei City, Taiwan/San Francisco, CA. The announcement, made via GlobeNewswire on Sept. 03, 2026, informs investors of the company's upcoming participation in the virtual investor event.
Why it matters — MENS watchers would care because the roadshow gives them a scheduled opportunity to hear directly from Jyong Biotech management about the company's business.
As at 29 Oct 2026, Jyong Biotech Ltd. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (70 of 100).
No analyst covering Jyong Biotech Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MENS are extrapolating price history, which says nothing about the business.
Jyong Biotech Ltd. returned -96.2% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Jyong Biotech Ltd. is a Taiwan-based biotechnology company focused on developing and commercializing plant-derived medicines for urinary system diseases.
The most recent item we track (GlobeNewsWire, 21 Oct 2026): "Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California". Jyong Biotech announced two investor events: Oct. 24, 2026, in Mountain View, California, and Oct. 25, 2026, in Irvine, California.
Jyong Biotech Ltd. is a Taiwan-based biotechnology company focused on developing and commercializing plant-derived medicines for urinary system diseases. Its current product pipeline includes candidate therapies for benign prostatic hyperplasia and lower urinary tract symptoms, prostate cancer, and interstitial cystitis or bladder pain syndrome. The company concentrates on botanical drug development, combining research and commercialization efforts around differentiated therapeutics designed for unmet medical needs. Jyong Biotech Ltd. operates with an initial commercial focus on the United States, the European Union, and Asia, including Taiwan and mainland China. As a specialized biopharmaceutical firm, it plays a role in advancing novel natural-origin treatments within the broader pharmaceuticals and biotechnology market.
CEO Ms. Fu-Feng Kuo · 27 employees · Taiwan · https://jyongbio.com
